Differential outcome of MEK1/2 inhibitor-platinum combinations in platinum-sensitive and -resistant ovarian carcinoma cells

New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening

Philip Skehan, Ritsa Storeng, Dominic A. Scudiero et al. · JNCI Journal of the National Cancer Institute · 1990 · 9.8K citations

Medicine, Oncology, Pharmacology +10

Integrated genomic analyses of ovarian carcinoma

Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text

Medicine, Genetics, Oncology +14

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Ting‐Chao Chou, Paul Talalay · Advances in Enzyme Regulation · 1984 · 7.2K citations

Pharmacy, Pharmacokinetics, Pharmacology +16

A leucine‐rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking

Jayne M. Stommel, Natalie D. Marchenko, Gretchen S. Jimenez et al. · The EMBO Journal · 1999 · 732 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +17

ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation

Jer-Yen Yang, Cong S. Zong, Weiya Xia et al. · Nature Cell Biology · 2008 · 699 citations

Medicine, Cancer Biology, Cell Biology +12